|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Iron deficiency is a common etiology of anemia that causes suboptimal response to erythropoietin therapy in hemodialysis (HD) patients.
|
31679114 |
2020 |
|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-dose erythropoietin (EPO) administration to hemodialysis (HD) patients with EPO hyporesponsiveness, due to iron deficiency, hyperparathyroidism, malnutrition, inflammation, and inadequate HD, results in increased risk of mortality and cardiovascular events.
|
31272526 |
2019 |
|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, iron deficiency and erythropoietin administration had additive effect on hepcidin gene downregulation in the liver.
|
30958854 |
2019 |
|
Iron deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we aimed to determine the associations between iron deficiency and higher EPO levels with mortality, and the potential mediating role of FGF23, in a cohort of community-dwelling subjects.
|
31170159 |
2019 |
|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with Hb between 10 and 13g/dL were classified as anaemic with or without iron deficiency and received iron or combination of iron and erythropoietin.
|
29887176 |
2019 |
|
Iron deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hepcidin and erythropoietin levels are intimately connected with inflammation and ID.
|
30941747 |
2019 |
|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Erythropoietin (EPO) is used to treat functional iron deficiency, and blood transfusion is restricted to refractory patients or in life-threatening emergency situations.
|
31614529 |
2019 |
|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lower EPO concentrations were associated with rapid eGFR decline, especially in patients with iron deficiency (P for interaction = 0.01).
|
31619722 |
2019 |
|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Erythropoietin is used in a few patients with anaemia to overcome functional iron deficiency, and blood transfusion is being restricted to refractory cases or acute life-threatening situations.
|
30544934 |
2018 |
|
Iron deficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dam-fed Fe-sufficient (IS) or postnatal ID groups were given daily subcutaneous sham or erythropoietic Epo injections (425 U<sup>.</sup> kg<sup>-1.</sup> d<sup>-1</sup> ), ± oral Fe (6 mg<sup>.</sup> kg<sup>-1.</sup> d<sup>-1</sup> ).
|
29696692 |
2018 |
|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most important factors leading to anemia in heart failure are inadequate erythropoietin production resulting from renal failure, intrinsic bone marrow defects, medication use, and nutritional deficiencies such as iron deficiency.
|
29128254 |
2018 |
|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients on exogenous EPO therapy and patients with iron deficiencies were excluded.
|
30136086 |
2018 |
|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
EPO-induced hypertension, at least in part, appears to be independent of an increase in hemoglobin, because experiments show that hemoglobin may be increased by EPO without an increase in blood pressure (BP) by simply treating the animals with EPO-binding protein and that treatment with EPO in the setting of iron deficiency may not increase hemoglobin but may still increase BP.
|
29228345 |
2018 |
|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Complications include anaemia due to reduced production of erythropoietin by the kidney; reduced red blood cell survival and iron deficiency; and mineral bone disease caused by disturbed vitamin D, calcium, and phosphate metabolism.
|
27887750 |
2017 |
|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is largely attributed to decreased erythropoietin (EPO) production and iron deficiency.
|
26268514 |
2015 |
|
Iron deficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In line with previous results, in patients without acute inflammation and severe iron deficiency the "high hepcidin" 736 V TMPRSS6 variant was associated with higher erythropoietin maintenance dose (p = 0.016), independently of subclinical inflammation (p = 0.02).
|
23433094 |
2013 |
|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
In mk/mk mice, erythropoietin administration increased activation of signal transducer and activator of transcription 5 (STAT5) and reduced apoptosis in bone marrow and spleen erythroblasts. mk/mk mice propagated on the 129S6/SvEvTac background resembled DMT1-mutant patients in having increased plasma iron but differed by having functional iron deficiency after erythropoietin administration.
|
22580996 |
2012 |
|
Iron deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular mechanisms leading to anemia during acute rejection are not fully understood; inadequate erythropoietin production and iron deficiency have been reported to be the main contributors.
|
12492705 |
2003 |